In our latest whitepaper, a recent study shows that BLIS K12™ stimulates the production of antibodies specific to SARS CoV-2 virus in people that have been vaccinated for COVID-19 and led to accelerated viral clearance.

A second study showed that participants taking BLIS K12™ showed reduced symptoms of COVID-19, including lower supplemental oxygen requirements and a lower death rate, compared to patients who received standard care.